Day One Biopharmaceuticals, Inc. (DAWN) Social Stream
DAY ONE BIOPHARMACEUTICALS INC (DAWN) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering DAWN.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 4 | $37 | $32 | $34.666 | $14.32 | 142.08% |
| 2022-03-07 | 4 | $38 | $32 | $35 | $14.32 | 144.41% |
| 2022-03-31 | 4 | $35 | $32 | $33 | $14.32 | 130.45% |
| 2022-05-16 | 4 | $35 | $31 | $32.666 | $14.32 | 128.11% |
| 2022-06-14 | 4 | $35 | $31 | $33.666 | $14.32 | 135.1% |
| 2022-08-08 | 4 | $40 | $31 | $35.333 | $14.32 | 146.74% |
| 2022-11-08 | 4 | $40 | $32 | $35.666 | $14.32 | 149.06% |
| 2022-11-09 | 4 | $40 | $35 | $37 | $14.32 | 158.38% |
| 2022-12-01 | 5 | $40 | $34 | $36.25 | $14.32 | 153.14% |
| 2022-12-05 | 6 | $40 | $34 | $36.25 | $14.32 | 153.14% |
| 2022-12-15 | 8 | $45 | $34 | $37.857 | $14.32 | 164.36% |
| 2023-01-27 | 8 | $62 | $34 | $42.857 | $14.32 | 199.28% |
| 2023-03-26 | 10 | $62 | $34 | $42.5 | $14.32 | 196.79% |
| 2023-04-05 | 10 | $62 | $34 | $43 | $14.32 | 200.28% |
| 2023-05-02 | 10 | $62 | $9 | $39.875 | $14.32 | 178.46% |
| 2023-06-05 | 10 | $62 | $9 | $39.375 | $14.32 | 174.97% |
| 2023-08-08 | 10 | $62 | $9 | $40 | $14.32 | 179.33% |
| 2023-08-11 | 10 | $54 | $9 | $38.25 | $14.32 | 167.11% |
| 2023-10-30 | 10 | $54 | $9 | $38 | $14.32 | 165.36% |
| 2023-11-07 | 10 | $54 | $10 | $38.25 | $14.32 | 167.11% |
| 2023-11-10 | 10 | $54 | $10 | $37.75 | $14.32 | 163.62% |
| 2023-11-15 | 10 | $54 | $10 | $37.375 | $14.32 | 161% |
The Trend in the Analyst Price Target
Over the past 12 months, DAWN's average price target has gone up $1.71.
DAWN reports an average of 175.04% for its upside potential over the past 44 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-08-08 | 10 | 62 | 9 | 40.00 | 13.07 | 206.04% |
| 2023-08-11 | 10 | 54 | 9 | 38.25 | 13.45 | 184.39% |
| 2023-10-30 | 10 | 54 | 9 | 38.00 | 11.90 | 219.33% |
| 2023-10-30 | 10 | 54 | 10 | 38.25 | 11.90 | 221.43% |
| 2023-11-07 | 10 | 54 | 10 | 37.75 | 12.36 | 205.42% |
DAWN Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.6 | 7 | 1 | 1 | 0 | 0 | 10 |
The Trend in the Broker Recommendations
Over the past 39 weeks, DAWN's average broker recommendation rating worsened by 0.3.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In terms of how DAY ONE BIOPHARMACEUTICALS INC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is higher than 2221.99% of that group.
- To contextualize these metrics, consider that out of all US stocks, DAY ONE BIOPHARMACEUTICALS INC's variance in analysts' estimates is lower than -1287.86% of them.
- DAWN has a greater average analyst price target than 2147.63% of stocks in the small market cap category.
- In terms of how DAY ONE BIOPHARMACEUTICALS INC fares relative to stocks in the small market cap category, note that its number of analysts covering the stock is greater than 1935.33% of that group.
In the Pharmaceutical Products industry, CNTA, ALZN, and CYT are the three stocks most similar to DAY ONE BIOPHARMACEUTICALS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is DAWN a Buy, Hold or Sell? See the POWR Ratings now!